iRadimed (NASDAQ:IRMD) Posts Earnings Results, Meets Expectations

iRadimed (NASDAQ:IRMD) announced its earnings results on Monday. The medical equipment provider reported $0.43 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.43, Zacks reports. iRadimed had a return on equity of 23.30% and a net margin of 26.61%. iRadimed updated its Q4 2025 guidance to 0.470-0.510 EPS and its FY 2025 guidance to 1.840-1.880 EPS.

iRadimed Price Performance

Shares of IRMD stock traded up $3.57 during trading hours on Monday, reaching $80.38. 18,015 shares of the company’s stock were exchanged, compared to its average volume of 46,972. The company has a market cap of $1.02 billion, a P/E ratio of 49.55 and a beta of 1.02. The company’s 50 day moving average is $73.14 and its two-hundred day moving average is $63.84. iRadimed has a 1 year low of $47.48 and a 1 year high of $82.25.

Analysts Set New Price Targets

A number of analysts recently issued reports on IRMD shares. Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Roth Capital set a $90.00 price objective on iRadimed in a research report on Friday. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of iRadimed in a research report on Friday. One analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $81.00.

Insider Buying and Selling

In other news, CEO Roger E. Susi sold 5,000 shares of the stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $77.69, for a total transaction of $388,450.00. Following the completion of the transaction, the chief executive officer directly owned 2,327,500 shares of the company’s stock, valued at approximately $180,823,475. This represents a 0.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Monty K. Allen sold 1,102 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $69.10, for a total value of $76,148.20. Following the transaction, the director directly owned 19,898 shares of the company’s stock, valued at approximately $1,374,951.80. This trade represents a 5.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 36,102 shares of company stock valued at $2,623,848. Company insiders own 36.80% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Several hedge funds have recently bought and sold shares of IRMD. Tower Research Capital LLC TRC increased its stake in iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 495 shares in the last quarter. Osaic Holdings Inc. increased its stake in iRadimed by 766.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,813 shares of the medical equipment provider’s stock valued at $228,000 after purchasing an additional 3,373 shares in the last quarter. Prudential Financial Inc. purchased a new position in iRadimed in the 2nd quarter valued at approximately $240,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in iRadimed by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock valued at $252,000 after purchasing an additional 234 shares in the last quarter. Finally, Brevan Howard Capital Management LP purchased a new position in iRadimed in the 2nd quarter valued at approximately $260,000. 92.34% of the stock is owned by hedge funds and other institutional investors.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.